Kyntra Bio Appoints Director; CEO Change‑in‑Control Agreement Extended

What Happened
Kyntra Bio, Inc. announced board and executive arrangement changes in a Form 8‑K filed Oct 1, 2026. Effective October 1, 2026, the Board appointed Andrew E. Singer, MBA, as a Class III director and added him to the Audit Committee; his term expires in 2029 and he will receive the Company’s non‑employee director compensation. Effective September 30, 2026, Maykin Ho, Ph.D., resigned from the Board (not due to any disagreement with management). Also on September 30, 2026, the Company entered a new Change‑in‑Control and Severance Agreement with CEO Thane Wettig replacing the prior agreement (which would have expired Oct 2, 2026); the new agreement runs through Oct 2, 2029 and contains no material changes to compensation or benefits.

Key Details

• Andrew E. Singer appointed Class III director and added to the Audit Committee, effective Oct 1, 2026; term expires 2029; will be covered by Company indemnity agreement.
• Maykin Ho resigned effective Sept 30, 2026; served on the Board since Dec 2018 and was a former Audit Committee member; resignation not due to disagreement with the Company.
• New Change‑in‑Control and Severance Agreement with CEO Thane Wettig executed Sept 30, 2026; three‑year term ending Oct 2, 2029; described as substantially the same as prior agreement and with no material change in pay/benefits.
• Press release announcing the director appointment was attached as an exhibit to the 8‑K.

Why It Matters
These are governance and executive‑level developments investors should note. The board gains a director with biopharma investment banking and transaction experience (Andrew Singer), which the company highlights as relevant to its oncology and rare‑disease focus. The departure of long‑time director Maykin Ho removes a source of financial and international commercialization experience from the Board. The new CEO change‑in‑control agreement preserves continuity of executive protections and contains no material increase in compensation, meaning the filing does not disclose additional immediate cash or equity obligations tied to the new agreement.